Reata Pharmaceuticals Inc

Reata Pharmaceuticals — Q1 2023 Earnings Presentation

36 slides from Reata Pharmaceuticals's earnings presentation, May 10, 2023

  1. Slide 1: 1st Quarter 2023 Financial Results and Update on Operational Progress and Development Programs

    1st Quarter 2023 Financial Results and Update on Operational Progress and Development Programs May 10, 2023 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation contains certain “forward‐looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward‐looking statements, including statements reg

  3. Slide 3: Today's Agenda

    Today’s Agenda Opening Remarks | Warren Huff, CEO U.S. Commercial Update | Dawn Bir, Chief Commercial Officer Regulatory Update | Andrea Loewen, SVP, Regulatory Affairs Development Update | Seemi Khan, Chief Medical Officer Development Update | Colin Meyer, Chief Innovation Officer Operational & Fin

  4. Slide 4: SKYCLARYS Approval

    SKYCLARYS® Approval 1SKYCLARYS® (omaveloxolone) See Full Prescribing information; FDA: U.S. Food and Drug Administration; FA: Friedreich’s ataxia; HCP: Health care provider; PK: Pharmacokinetics; EMA: European Medicines Agency SKYCLARYS is the first and only FDA approved therapy indicated for patien

  5. Slide 5: Neurology Pipeline Updates

    Neurology Pipeline Updates MAA: Marketing Authorization Application; Nrf2: Nuclear factor-erythroid factor 2-related factor 2; DPNP: Diabetic Peripheral Neuropathic Pain MAA for omaveloxolone for patients with FA in Europe submitted in Q4 2022 Received Day 120 List of Questions (LOQ) On track to sub

  6. Slide 6: Bardoxolone and Corporate Updates

    Bardoxolone and Corporate Updates ESRD: End-stage renal disease; CKD: Chronic kidney disease Kyowa Kirin reported results from AYAME, Phase 3 trial of bardoxolone in patients with diabetic kidney disease Met primary and key secondary endpoints with no significant safety issues No separation in ESRD

  7. Slide 7: U.S. Commercial Update

    U.S. Commercial Update

  8. Slide 8: U.S. Market Opportunity and HCP Launch Landscape

    U.S. Market Opportunity and HCP Launch Landscape 1CCRN: Collaborative Clinical Research Network in Friedreich’s ataxia, https://curefa.org/network; ; 2https://www.ataxia.org/neurologists-and-specialty-clinics/; 32023 FA Claims analysis; 4NIH Friedreich Ataxia Fact Sheet (Accessed 2/2023); 5Estimated

  9. Slide 9: U.S. Early Demand Reflects Engaged HCPs and Patients

    U.S. Early Demand Reflects Engaged HCPs and Patients Patient and HCP communities have awaited a treatment for FA ~500 Patient Start Forms Received by Reata REACH patient services SKYCLARYS Launch Performance Through May 10 SKYCLARYS Payer Coverage Progressing as Expected Payer approval for coverage

  10. Slide 10: 2023 U.S. Launch Commercial Strategy

    2023 U.S. Launch Commercial Strategy Establish SKYCLARYS as the first effective and safe treatment approved for Friedreich’s ataxia Communicate the value of SKYCLARYS to HCPs who treat FA Activate FA patients to proactively seek SKYCLARYS treatment Facilitate coverage, access and affordability 1 2 3

  11. Slide 11: U.S. Market Access and Sales Force Execution

    U.S. Market Access and Sales Force Execution Neurology Sales Force Patient Access Team Our Field Sales Team: ~2,500 U.S. HCP Targets Deployed fully trained and experienced U.S. field sales team March 6th ~2,500 sales force target HCPs treat the majority of diagnosed U.S. Friedreich's ataxia patients

  12. Slide 12: Regulatory Update

    > = " [s Regulatory > ve Update sss REATA. ee @ rhanwaceuticats

  13. Slide 13: SKYCLARYS Drug Availability

    SKYCLARYS Drug Availability NDA supplement submitted in Q2 2023 to add a limit to the drug substance specification for a process impurity observed above the approved specification for unspecified impurities during commercial scale API validation SKYCLARYS drug product manufacturing and testing succe

  14. Slide 14: FDA Review Considerations

    FDA Review Considerations NDA Supplement Low safety risk Limit below the FDA Qualification Threshold? Detectable? Structure identified? No impact on total impurities? Physical properties unchanged? FDA assesses each impurity specification on a case-by-case basis to determine the potential impact of

  15. Slide 15: Omaveloxolone MAA Status

    Omaveloxolone MAA Status CMC: Chemistry, manufacturing, and controls MAA submitted in Europe for omaveloxolone for the treatment of Friedreich’s ataxia in Q4 2022 Received Day 120 List of Questions (LOQ) Primary feedback mechanism regarding EMA’s review of the MAA Day 120 responses primary mechanism

  16. Slide 16: Pediatric Expansion Plans

    Pediatric Expansion Plans sss REATA. eco OOO rictwcceuticacs

  17. Slide 17: Omaveloxolone Plans for Pediatric Studies in FA

    Omaveloxolone Plans for Pediatric Studies in FA PIP: Pediatric investigation plan Evaluating strategies to support global label expansion for pediatric patients Pediatric development plans in Europe Received positive opinion on PIP from the Pediatric Committee Based on agreement in the PIP, request

  18. Slide 18: Neurology Pipeline Updates

    Neurology Pipeline Updates Ses es

  19. Slide 19: Nrf2 Activator Pharmacology May be Applicable to a Broad Set of Neurological Diseases

    Mitochondrial dysfunction, neuroinflammation, and neurodegeneration are common features of neurological diseases Genetic or pharmacologic activation of Nrf2 has demonstrated activity in multiple preclinical models that demonstrate effects on: Mitochondrial function Neuroinflammation Neurodegeneratio

  20. Slide 20: Overview & Status of Next Generation Nrf2 Activator Program

    Overview & Status of Next Generation Nrf2 Activator Program ADME: absorption, distribution, metabolism, and excretion; PK: Pharmacokinetics; IND: Investigational New Drug Application Have advanced two next generation Nrf2 activators, RTA 415 and RTA 417, to IND-directed studies Structure-activity re

  21. Slide 21: Cemdomespib: Hsp90 Modulator for DPNP

    Cemdomespib: Hsp90 Modulator for DPNP Cemdomespib (RTA 901) is a highly potent and selective, oral, small-molecule modulator of Hsp90 Differentiated from N-terminal Hsp90 inhibitors and promotes mitochondrial function Active in preclinical models of painful and insensate diabetic neuropathy1 DPNP is

  22. Slide 22: Cemdomespib: Phase 2 Trial Design

    Cemdomespib: Phase 2 Trial Design Randomized, double-blind, placebo-controlled, two-part, 12-week Phase 2 trial of cemdomespib in patients with DPNP Objective is to assess pain using the numeric pain rating scale (NPRS) Plan to enroll 192 patients in each of Part 1 and Part 2 Patients allowed to tak

  23. Slide 23: Bardoxolone Update

    Bardoxolone Update

  24. Slide 24: AYAME Purpose and Design

    AYAME Purpose and Design Conducted to determine if eGFR improvements translate to reductions in ESRD Phase 3, randomized, double-blind, placebo-controlled trial in diabetic kidney disease Enrolled patients with advanced CKD (eGFR of ≥15.0 to <60.0 mL/min/1.73 m2) Treatment duration of 3 to 4 years w

  25. Slide 25: AYAME Efficacy Results

    AYAME Efficacy Results Primary and key secondary composite endpoints demonstrated statistical significance favoring bardoxolone Driven by reductions in 30% and 40% eGFR decline events No separation in ESRD events AYAME data showing improvements in eGFR-based endpoints without a trend in ESRD pose a

  26. Slide 26: AYAME Safety Overview

    Safety data provide important data for the broader Nrf2 activator class Renal safety: no evidence of hyperfiltration or adverse renal safety CV safety: no evidence of adverse CV safety with no imbalances in Deaths Adjudicated CV events SAEs Fluid overload events Blood pressure Liver safety: no evide

  27. Slide 27: Operational and Financial Updates

    Operational and Financial Updates

  28. Slide 28: Operational Update

    Operational Update Drug product manufacturing completed Packaging and labeling of SKYCLARYS bottles completed Anticipate SKYCLARYS commercial drug supply availability through the specialty pharmacy no later than mid-August 2023, subject to regulatory approval Ramped up production activities for the

  29. Slide 29: EU Update

    EU Update Continuing build-up of our EU infrastructure following submission of our MAA for omaveloxolone in Q4 2022 Hired EU headquarter leadership team: commercial, marketing, market access, medical affairs, and supply chain activities Initiated marketing activities, global value messaging, and hea

  30. Slide 30: BXLS Amendment Update

    BXLS Amendment Update BXLS: Blackstone Life Sciences Amended BXLS development agreement Removes all obligations for bardoxolone development and commercialization Removes restrictions on any new debt Removes restrictions on licensing any assets Released all prior security interests granted to BXLS Pr

  31. Slide 31: Financial Update

    Financial Update Completed $275 million debt financing agreement Initial tranche of $75 million to be funded on May 12, 2023 Second tranche of $50 million after meeting certain regulatory or production requirements Two final tranches of $75 million each to be borrowed based on commercial sales miles

  32. Slide 32: Financial Summary

    Financial Summary 1Excludes stock-based compensation expenses; 2Excludes various adjustments, including stock-based compensation expenses, non-cash interest expense from liability related to sale of future royalties; see the next slide for a reconciliation between GAAP and non-GAAP measures. GAAP: G

  33. Slide 33: Reconciliation of GAAP to Non-GAAP Financial Measures

    Reconciliation of GAAP to Non-GAAP Financial Measures

  34. Slide 34: Concluding Remarks

    Concluding Remarks

  35. Slide 35: Reata at a Glance

    Reata at a Glance With SKYCLARYS approval Reata is transitioning into a commercial enterprise Encouraging initial demand from patients and HCPs Drug availability expected no later than mid-August 2023 MAA for omaveloxolone under review in the EU Phase 2 trial of cemdomespib in patients with DPNP ant

  36. Slide 36: Thank you

    k you J \ yuu /

Reata Pharmaceuticals — Q1 2023 Earnings Presentation on 6ix